NEW YORK, March 10, 2023 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Organon & Co. (“Organon” or the “Company”) OGN. Those investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, extension 7980.

The investigation concerns whether Organon and certain of its officers and/or directors have engaged in securities fraud or other illegal business practices.

[Click here for information about joining the class action]

On February 16, 2023, Organon issued a press release announcing financial results for the fourth quarter and full year ended December 31, 2022. Among other things, Organon reported earnings per share of $0.81, down 28.3% year over year, and revenue of $1.49 billion, down 7.4% year over year. Organon also reported an $8 million decrease in sales of the Company’s established brands for the quarter due to the initiation of a market action in certain betamethasone suspension injection markets related to a non-compliant component of a manufacturing line at the Company’s Heist facility , Belgium .

As a result of this news, Organon’s stock price fell $4.39 per share, or 15%, to close at $24.87 per share on February 16, 2023.

The Pomerantz law firm, with offices in New York, Chicago, Los Angeles, London and Paris, is recognized as one of the leading law firms in the areas of corporate, securities and antitrust litigation. Founded by the late Abraham L. Pomerantz, known as Dean of the Class Attorney’s Association, the Pomerantz firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz law firm continues the tradition he established and fights for the rights of victims of securities fraud, breaches of fiduciary duty and corporate misconduct. The firm has recovered numerous multi-million dollar claims on behalf of group members. See www.pomerantzlaw.com.

CONTACT:
Robert S Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
888-476-6529 ext….